Eptinezumab IV for Migraine: Prospective Real-World Analysis
Prospective real-world analysis of intravenous eptinezumab in migraine patients confirms clinical trial efficacy translates to everyday practice with good tolerability.
Quick Facts
What This Study Found
Prospective real-world analysis of intravenous eptinezumab in migraine patients confirms clinical trial efficacy translates to everyday practice with good tolerability.
Key Numbers
Patients received eptinezumab 100 mg IV; treatment period up to 6 months. Specific migraine day reductions not detailed in abstract.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Prospective real-world analysis of intravenous eptinezumab in migraine patients confirms clinical tr
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience.
- Published In:
- The journal of headache and pain, 26(1), 235 (2025)
- Authors:
- Andreou, Anna P(2), Hill, Bethany, Al-Rawi, Rand, Murphy, Madeleine, Soares, Isabel, Briscoe, Jessica, Kilner, Rachael, Lambru, Giorgio
- Database ID:
- RPEP-09946
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Prospective real-world analysis of intravenous eptinezumab in migraine patients confirms clinical trial efficacy translates to everyday practice with good tolerability.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09946APA
Andreou, Anna P; Hill, Bethany; Al-Rawi, Rand; Murphy, Madeleine; Soares, Isabel; Briscoe, Jessica; Kilner, Rachael; Lambru, Giorgio. (2025). A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience.. The journal of headache and pain, 26(1), 235. https://doi.org/10.1186/s10194-025-02180-3
MLA
Andreou, Anna P, et al. "A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience.." The journal of headache and pain, 2025. https://doi.org/10.1186/s10194-025-02180-3
RethinkPeptides
RethinkPeptides Research Database. "A prospective real-world analysis of intravenous eptinezumab..." RPEP-09946. Retrieved from https://rethinkpeptides.com/research/andreou-2025-a-prospective-realworld-analysis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.